Clovis shares tank after investors size up the disappointing data on rucaparib
Clovis Oncology’s shares got hammered this morning after the biotech revealed some mixed results for its PARP inhibitor rucaparib.
The biotech reported a 54% objective response rate for the drug for BRCA-mutated ovarian cancer, with nine (9%) complete responders and 48 (45%) partial responders. Boring down into the data, investigators also reported zero response among the 7% of the patients who were platinum-refractory, a 25% response rate for platinum-resistant patients and 66% for platinum-sensitive responses.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
